证券代码：688513 证券简称：苑东生物 公告编号：2025-047 成都苑东生物制药股份有限公司 关于变更独立董事的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 成都苑东生物制药股份有限公司（以下简称"公司"）于 2025 年 7 月 16 日 召开了第四届董事会第六次会议，审议通过了《关于免去彭龙先生独立董事职 务的议案》、《关于补选公司第四届董事会独立董事的议案》，现将具体内容公告 如下： 一、变更独立董事情况 董事会 2025 年 7 月 17 日 2 鉴于公司独立董事彭龙先生因个人原因目前正在接受纪律审查和监察调查， 无法正常履职，为保证公司董事会的正常运作，根据《上海证券交易所科创板 上市公司自律监管指引第 1 号——规范运作》《上市公司独立董事管理办法》以 及《公司章程》等相关规定，董事会决定免去彭龙先生的独立董事职务及其在 董事会各专门委员会中担任的全部职务，免职后，彭龙先生将不再担任公司任 何职务。彭龙先生独立董事职务免职事项自公司股东大会审议通过之日起生效。 鉴于公司免去彭龙先生独立董事的职务 ...

（二）《中华人民共和国公务员法》关于公务员兼任职务的 规定（不适用）； 独立董事提名人声明与承诺 提名人成都苑东生物制药股份有限公司控股股东、实际控制 人王颖，现提名李卫锋为成都苑东生物制药股份有限公司第四届 董事会独立董事候选人，并已充分了解被提名人职业、学历、职 称、详细的工作经历、全部兼职、有无重大失信等不良记录等情 况。被提名人已同意出任成都苑东生物制药股份有限公司第四届 董事会独立董事候选人（参见该独立董事候选人声明）。提名人 认为，被提名人具备独立董事任职资格，与成都苑东生物制药股 份有限公司之间不存在任何影响其独立性的关系，具体声明并承 诺如下： 一、被提名人具备上市公司运作的基本知识，熟悉相关法律、 行政法规、规章及其他规范性文件，具有 5 年以上法律、经济、 会计、财务、管理或者其他履行独立董事职责所必需的工作经验， 并已根据《上市公司高级管理人员培训工作指引》及相关规定完 成了独立董事履职学习，具备独立董事任职资格。 二、被提名人任职资格符合下列法律、行政法规和部门规章 的要求： （一）《中华人民共和国公司法》关于董事任职资格的规定； （三）中国证监会《上市公司独立董事管理办法》、上海证 ...

证券代码：688513 证券简称：苑东生物 公告编号：2025-048 成都苑东生物制药股份有限公司 关于召开2025年第一次临时股东大会的通知 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、 召开会议的基本情况 （一） 股东大会类型和届次 2025年第一次临时股东大会 （二） 股东大会召集人：董事会 至2025 年 8 月 1 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东大会召开当日的交易时间段，即 9:15-9:25,9:30-11:30，13:00-15:00；通过互联 网投票平台的投票时间为股东大会召开当日的 9:15-15:00。 股东大会召开日期：2025年8月1日 本次股东大会采用的网络投票系统：上海证券交易所股东大会网络投票 系统 （六） 融资融券、转融通、约定购回业务账户和沪股通投资者的投票程序 （三） 投票方式：本次股东大会所采用的表决方式是现场投票和网络投票相结 合的方式 （四） 现场会议召开的日期、时间和地点 召开日期时间：2025 年 8 月 1 ...

二、董事会会议审议情况 经与会董事审议，逐项表决，形成决议如下： 证券代码：688513 证券简称：苑东生物 公告编号：2025-046 成都苑东生物制药股份有限公司 第四届董事会第六次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、董事会会议召开情况 成都苑东生物制药股份有限公司（以下称"公司"）第四届董事会第六次会议 于 2025 年 7 月 16 日以现场和通讯相结合的方式召开。会议通知已于 2025 年 7 月 14 日以专人送达、电话通知、电子邮件等形式临时送达全体董事。本次会议 由董事长王颖女士主持，应出席董事 9 名，实际出席董事 8 名，独立董事彭龙先 生因正在接受纪律审查和监察调查未参加会议。本次会议的召集、召开和表决程 序符合《中华人民共和国公司法》等相关法规和《成都苑东生物制药股份有限公 司章程》的规定，会议形成的决议合法有效。 （一）审议通过《关于免去彭龙先生独立董事职务的议案》 （二）审议通过《关于补选公司第四届董事会独立董事的议案》 本议案已经董事会提名委员会审议通过。 鉴于公 ...

Group 1 - Shengde Xintai won a bid for a thermal power steel pipe project worth approximately 217 million yuan, accounting for 8.15% of its audited revenue for 2024 [1] - High-speed Electric's subsidiary won a project for the Shanghai-Nanjing-Hefei high-speed railway, with a bid amount of 71.76 million yuan [1] - Cangge Mining's subsidiary received a construction permit for a lithium-boron mining project, with a construction area of 106,900 square meters [2] Group 2 - China Electric Power Construction signed a mining transportation project contract in Guinea worth approximately 5.063 billion yuan, with a total duration of about 72 months [3] - Guobang Pharmaceutical's subsidiary completed the registration of an equity investment fund focusing on strategic emerging industries [4] - Deshi Co. obtained two invention patents related to oil and gas field development [5][26] Group 3 - Xue Tian Salt Industry expects a significant decrease in net profit for the first half of 2025, projecting a decline of 76.34% to 80.29% [6] - Rundu Co. received a drug registration certificate for moxifloxacin hydrochloride tablets, used for treating various bacterial infections [7] - China Nuclear Power reported a 15.65% increase in power generation in the first half of the year, with nuclear power generation up by 12.01% [8] Group 4 - Suqian Liansheng obtained two invention patents related to wastewater treatment methods [9] - Boshi Co. signed a 109 million yuan operation and maintenance service contract for solid product packaging [11] - *ST Sailong's subsidiary received a drug registration certificate for torasemide injection, used for various medical conditions [13] Group 5 - North Bay Port reported a 10.95% increase in cargo throughput for the first half of 2025, with container throughput also showing growth [14] - Kaiwei Te expects a revenue increase of 56.17% to 90.87% for the first half of 2025 [15] - Wankai New Materials plans to reduce production and conduct maintenance on 60,000 tons of PET capacity, affecting overall performance [16] Group 6 - Haiwang Bio's HW130 injection successfully completed Phase I clinical trials, showing good safety and tolerability [19] - Zhenai Meijia received a total of 22.8 million yuan in compensation for land acquisition, which will significantly impact its 2025 performance [20] - Changyuan Electric reported a 23.58% decrease in power generation in June, with a notable decline in thermal power generation [21] Group 7 - Shouxiangu's subsidiary completed the registration of two health food products [22] - Kailun Co. announced the resignation of its deputy general manager and board secretary [23] - Xibu Muye reported a 2.15% year-on-year increase in fresh milk production in June [24] Group 8 - Deshi Co. obtained two invention patents related to oil and gas field development [26] - Jingwei Huikai plans to acquire a 12.44% stake in Nuo Si Micro for 149 million yuan [27] - Electric Alloy completed the registration of its subsidiary in Mexico [29] Group 9 - Meinuohua expects a net profit increase of 142.84% to 174.52% for the first half of 2025 [30] - Guizhou Moutai repurchased approximately 3.38 million shares, accounting for 0.2692% of its total share capital [31][32] - Warner Pharmaceutical received approval for the listing application of a raw material drug for treating respiratory diseases [34] Group 10 - Yuan Dong Bio's independent director is under investigation for serious violations [35] - Dash Intelligent signed a contract for a smart project worth 11.88 million yuan [36] - Dayou Energy plans to transfer 586,500 tons of coal production capacity replacement indicators [37] Group 11 - Foton Motor reported a 150.96% increase in new energy vehicle sales in the first half of 2025 [39] - Renfu Pharmaceutical's shareholder plans to increase its stake by 1% to 2% [40] - Zongshen Power expects a net profit increase of 70% to 100% for the first half of 2025 [42] Group 12 - Yingboer plans to sell its wholly-owned subsidiary for 239 million yuan [44] - Changan Automobile reported a 1.59% increase in total vehicle sales in the first half of 2025 [46] - Fulian Precision signed a cooperation framework agreement with Sichuan Development Longmang [48] Group 13 - Nengte Technology plans to repurchase shares worth 300 million to 500 million yuan [50] - Longsoft Technology's controlling shareholder donated 3.43% of the company's shares [51] - Data Port's shareholders plan to reduce their holdings by up to 2% [52]

Group 1 - Independent director Peng Long of New Hope, Yuandong Bio, and Digital China is under investigation for serious violations of discipline and law [1][2] - Peng Long has held various academic and administrative positions, including professor and doctoral supervisor at Southwest University of Finance and Economics [1] - In 2024, Peng Long received pre-tax compensation of 100,000 yuan from New Hope, 240,000 yuan from Yuandong Bio, and 132,800 yuan from Digital China [2] Group 2 - All three companies confirmed that Peng Long only performed duties at the board level and did not participate in specific business operations [2] - New Hope stated that Peng Long "does not participate in the daily management of the company" [2] - Digital China and Yuandong Bio emphasized that his responsibilities "do not involve the daily operations of the company" [2]

Policy Developments - The National Healthcare Security Administration (NHSA) is soliciting public opinions on the draft adjustment plan for the 2025 National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance drug catalog, as well as the commercial health insurance innovative drug catalog [2] - The first version of the commercial health insurance innovative drug catalog will be established in 2025, focusing on innovative drugs with high clinical value that cannot be included in the basic catalog [2] Drug and Device Approvals - JinSai Pharmaceutical's monoclonal antibody drug, Firsekibart, has been approved for the treatment of acute gouty arthritis in adults who are intolerant to or have contraindications for non-steroidal anti-inflammatory drugs and/or colchicine [4] - Betta Pharmaceuticals' innovative drug, Tazemetostat, has been approved for the treatment of locally advanced or metastatic breast cancer in adults who have progressed after endocrine therapy [5] - Xiansheng Pharmaceutical's monoclonal antibody, Suweisitabant, has been approved for the treatment of recurrent ovarian cancer, fallopian tube cancer, or primary peritoneal cancer in adults who have received no more than one prior systemic therapy [6] Capital Markets - Merida Biosciences, a U.S. biotech company, has raised $121 million in Series A financing, setting a record for Series A funding in the autoimmune field [8] Industry Events - Former Takeda China President, Dan Guohong, will join BeiGene as General Manager for Greater China, Central Asia, and South Asia, starting August 18, 2025 [10] - Yuan Dong Bio's independent director, Peng Long, is under disciplinary review and investigation for serious violations of discipline and law [12] - KangLe WeiShi announced that its shareholder, Tianlangxing Holdings Group, has reduced its holdings by 1.6953 million shares, accounting for 0.6034% of the company's total share capital [13]

Group 1 - Guizhou Moutai has repurchased a total of 3.3821 million shares as of June 30, 2025, accounting for 0.2692% of the total share capital, with a total expenditure of 5.202 billion yuan [2] - Luxshare Precision is planning to issue H-shares and list on the Hong Kong Stock Exchange to enhance its global financing capabilities and governance transparency [2] - Huazhong Xinchuang has received a project notification from a leading domestic eVTOL manufacturer for the development and supply of an intelligent cockpit multimedia display system [3] Group 2 - Meinohua expects a net profit of 46 million to 52 million yuan for the first half of 2025, representing a year-on-year increase of 142.84% to 174.52% [4] - Jiangnan Water has received a report from shareholder Lianan Life Insurance indicating an increase in shareholding by 46.99 million shares, representing 5.03% of the total share capital [5] - Huasen Pharmaceutical has received approval for clinical trials of its CX001 sustained-release tablets, marking a milestone for its innovative drug development platform [6] Group 3 - Zongshen Power anticipates a net profit growth of 70% to 100% for the first half of the year [7] - Yutong Bus reported a sales volume of 5,919 units in June, a year-on-year increase of 24.79% [7] - Guangzhou Port expects a 7.0% year-on-year increase in container throughput for June 2025 [7] Group 4 - Data Port's shareholders plan to reduce their holdings by up to 1.74% and 0.26% of the company's shares [9] - Humanwell Healthcare's shareholder plans to increase its stake by 1% to 2% [9] - Nengte Technology plans to repurchase shares worth between 300 million to 500 million yuan [10]

Core Viewpoint - The independent director Peng Long of New Hope, Yuandong Bio, and Digital China is under investigation for serious violations of discipline and law, but this situation is not expected to significantly impact the companies' operations [1][2]. Group 1: Company Announcements - New Hope announced that its independent director, Peng Long, is under investigation by the Central Commission for Discipline Inspection and the Shanxi Provincial Supervisory Commission, but his role does not involve daily management, thus not affecting the company's operations [1]. - Digital China also reported that Peng Long is under investigation, emphasizing that he does not participate in the company's daily operations, which will not have a significant impact on the company's business activities [1]. - Yuandong Bio confirmed that Peng Long is under investigation and reiterated that he does not engage in the company's daily management, ensuring that the investigation will not significantly affect the company's operations [2]. Group 2: Peng Long's Roles - Peng Long serves as an independent director and holds various committee positions in New Hope, including the Compensation and Assessment Committee, Risk Control Committee, and Nomination Committee [1][2]. - In Digital China, Peng Long is an independent director and a member of the Audit Committee and the Strategy and ESG Committee [1][2]. - At Yuandong Bio, he is the independent director, the chair of the Strategy Committee, and a member of the Nomination and Audit Committees [2].

作 者丨尹华禄 编 辑丨陈思颖 刘雪莹 7月2日晚间，新希望也发布公司独董被查公告并表示，彭龙系公司独立董事，目前除担任公 司独立董事、董事会薪酬与考核委员会委员、董事会风险控制委员会委员、董事会提名委员 会委员外，未担任公司其他职务，不参与公司日常经营管理。上述事项不会对公司生产经营 活动产生重大影响。 苑东生物今年4月发布的年报显示，彭龙曾任西南财经大学党委常委、常务副校长等职务，西 南财经大学金融学院教授。现任西南财经大学金融学院博士生导师、东南大学首席教授、经 济管理学院教授、博士生导师，全国金融专业学位研究生教育指导委员会委员、教育部高等 学校专业设置与教学指导委员会主任委员等职位。2023年5月起任苑东生物独立董事。 公开资料显示，彭龙于1964年出生，毕业于中国科学院系统科学研究所应用数学专业，获博 士学位。1999年起享受国务院政府特殊津贴，2014年入选国家百千万人才工程，被授予"国家 有突出贡献中青年专家"称号。 值得一提的是，彭龙此前曾任北京外国语大学校长。 苑东生物、新希望双双公告：独立董事出事！ 7月2日，创新药上市公司苑东生物（688513.SH）发布公告称，公司于昨日（7月1日） ...